Osteoporos Int. 2016 May;27(5):1677-82. doi: 10.1007/s00198-016-3553-3. Epub 2016 Mar 1
Patients should be encouraged to continue denosumab therapy long term. If discontinuation does occur, appropriate steps must be taken to prevent the rapid bone loss and probable acute fracture risk.
Autor: Loi F, Córdova LA, Pajarinen J, Lin TH, Yao Z, Goodman SB.
